Maria Faelth-Savitski
Research Subjects
Maria Faelth-Savitski has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Marcus Bantscheff
Cellzome, A GSK company
57 shared publications - Giovanna Bergamini
Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, 69117 Heidelberg, Germany
56 shared publications - H. Christian Eberl
Cellzome, a GSK company, Meyerhofstrasse 1, 69117 Heidelberg, Germany
56 shared publications - Anna Rutkowska
Cellzome, a GSK Company, R&D, GSK, Heidelberg, Germany
55 shared publications - Massimo Petretich
Cellzome, GSK, R&D, Heidelberg, Germany. 1
55 shared publications - Paola Grandi
Cellzome, GSK, R&D, Heidelberg, Germany. 1
55 shared publications
Latest Publications
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S9 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Expression proteomic signature
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Expression proteomic signature
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Photo affinity labelling (PAL)
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Photo affinity labelling (PAL)
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Table S8 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Table S8 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Selectivity profile live cells (2D-TPP)
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Selectivity profile live cells (2D-TPP)
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
PanPARP matrix (affinity enrichment chemoproteomics)
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
PanPARP matrix (affinity enrichment chemoproteomics)
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Detection of 24,25-epoxycholesterol
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Detection of 24,25-epoxycholesterol
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Kinobead assay (affinity enrichment chemoproteomics)
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Kinobead assay (affinity enrichment chemoproteomics)
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Co-inhibition of PARP and cholesterol biosynthesis pathway increase efficiency of tumor cell killing
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Co-inhibition of PARP and cholesterol biosynthesis pathway increase efficiency of tumor cell killing
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Supplementary Materials and Methods
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Supplementary Materials and Methods
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Niraparib matrix (affinity enrichment chemoproteomics)
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Niraparib matrix (affinity enrichment chemoproteomics)